A new study found early hydroxychloroquine (HCQ) use offers no protection against preeclampsia or preterm birth in women with systemic lupus erythematosus (SLE).

Anifrolumab treatment is linked to improved disease activity and reduced steroid use and has an acceptable safety profile in routine care of patients with systemic lupus erythematosus.

Investigators studied GLP-1 receptor agonist use and renal and inflammatory outcomes among patients with systemic lupus erythematosus and type 2 diabetes mellitus.

With enpatoran soon entering Phase III clinical trials, the Phase II safety and efficacy results support the drug’s development.

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disorder in which the body’s immune system mistakenly attacks its own healthy tissues. This condition can affect multiple organs, including ...

The FDA has granted fast track designation to the anti-FcRn agent nipocalimab for the treatment of adults with systemic lupus ...

Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that predisposes affected individuals to an elevated risk of cardiovascular disease (CVD). The intricate interplay of traditional ...

Mitochondrial antibody profiling may help identify patients with SLE at increased risk for severe complications, including LN ...

Background/objective To reduce the risk of hydroxychloroquine (HCQ)-induced retinopathy, the American Academy of ...

Systemic lupus erythematosus (SLE) is an autoimmune disease, in which the immune system that normally protects the body from invading microbes turns against the body's own cells. Researchers studied ...

For the patient who presents with a new diagnosis of SLE, or for the one who has a flare in previously established disease, the immediate need is to achieve control of the inflammatory process. In ...